CA1219219A - Comprimes de fluorure de sodium a liberation progressive, methode de production desdits comprimes et methode de traitement de l'osteoporose - Google Patents

Comprimes de fluorure de sodium a liberation progressive, methode de production desdits comprimes et methode de traitement de l'osteoporose

Info

Publication number: CA1219219A
Authority: CA; Canada
Prior art keywords: parts; present; fluoride; talc; tablet
Prior art date: 1983-08-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000444788A

Other languages

English (en)

Inventor

Neill B. Walsdorf

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-08-11

Filing date

1984-01-05

Publication date

1987-03-17

1984-01-05 Application filed by Individual filed Critical Individual

1987-03-17 Application granted granted Critical

1987-03-17 Publication of CA1219219A publication Critical patent/CA1219219A/fr

Status Expired legal-status Critical Current

Links

PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 title claims abstract 17
235000013024 sodium fluoride Nutrition 0.000 title claims abstract 8
239000011775 sodium fluoride Substances 0.000 title claims abstract 8
238000000034 method Methods 0.000 title claims abstract 5
208000001132 Osteoporosis Diseases 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title 1
239000004203 carnauba wax Substances 0.000 claims abstract description 11
235000013869 carnauba wax Nutrition 0.000 claims abstract description 11
239000011159 matrix material Substances 0.000 claims abstract description 11
238000002156 mixing Methods 0.000 claims abstract description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract 21
239000000454 talc Substances 0.000 claims abstract 13
229910052623 talc Inorganic materials 0.000 claims abstract 13
235000019359 magnesium stearate Nutrition 0.000 claims abstract 10
239000002245 particle Substances 0.000 claims abstract 7
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 13
239000003513 alkali Substances 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
229940091249 fluoride supplement Drugs 0.000 claims 10
229960000414 sodium fluoride Drugs 0.000 claims 6
239000007970 homogeneous dispersion Substances 0.000 claims 3
150000001447 alkali salts Chemical group 0.000 claims 2
239000000203 mixture Substances 0.000 claims 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
239000001993 wax Substances 0.000 abstract description 7
239000007891 compressed tablet Substances 0.000 abstract 1
239000004615 ingredient Substances 0.000 abstract 1
239000003826 tablet Substances 0.000 abstract 1
LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 4
241000282337 Nasua nasua Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 2
241000219498 Alnus glutinosa Species 0.000 description 1
241000581444 Clinidae Species 0.000 description 1
101150039033 Eci2 gene Proteins 0.000 description 1
HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
101100270435 Mus musculus Arhgef12 gene Proteins 0.000 description 1
241001296096 Probles Species 0.000 description 1
235000014443 Pyrus communis Nutrition 0.000 description 1
101150107341 RERE gene Proteins 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
241000193803 Therea Species 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
101150085091 lat-2 gene Proteins 0.000 description 1
AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
235000015250 liver sausages Nutrition 0.000 description 1
206010037833 rales Diseases 0.000 description 1
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
239000008279 sol Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000444788A 1983-08-11 1984-01-05 Comprimes de fluorure de sodium a liberation progressive, methode de production desdits comprimes et methode de traitement de l'osteoporose Expired CA1219219A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US52201483A	1983-08-11	1983-08-11
US06/522,014		1983-08-11

Publications (1)

Publication Number	Publication Date
CA1219219A true CA1219219A (fr)	1987-03-17

Family

ID=24079076

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000444788A Expired CA1219219A (fr)	1983-08-11	1984-01-05	Comprimes de fluorure de sodium a liberation progressive, methode de production desdits comprimes et methode de traitement de l'osteoporose

Country Status (4)

Country	Link
JP (1)	JPS6042323A (fr)
CA (1)	CA1219219A (fr)
CH (1)	CH655851A5 (fr)
DE (1)	DE3343253A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0289314B1 (fr) *	1987-04-28	1994-10-12	Roche Diagnostics GmbH	Emploi de IGF-II pour le traitement de désordres des os
AU2003225649C1 (en) *	2003-03-04	2009-10-22	Nostrum Pharmaceuticals, Inc.	Control release formulation containing a hydrophobic material as the sustained release agent
CN103439377B (zh) *	2013-08-13	2015-12-09	江苏大学	一种NaF释放的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2805977A (en) *	1955-01-04	1957-09-10	Smith Kline French Lab	Sustained release pharmaceutical preparation
DE2630326C2 (de) *	1976-07-06	1983-07-21	"Gebro" G. Broschek Kg, Chemisch-Pharmazeutische Fabrik, 6391 Fieberbrunn, Tirol	Präparat zur Behandlung der Osteoporose und seine Herstellung

1983
- 1983-11-30 DE DE19833343253 patent/DE3343253A1/de active Granted
- 1983-12-14 CH CH6669/83A patent/CH655851A5/de not_active IP Right Cessation
1984
- 1984-01-05 CA CA000444788A patent/CA1219219A/fr not_active Expired
- 1984-05-21 JP JP59100727A patent/JPS6042323A/ja active Granted

Also Published As

Publication number	Publication date
CH655851A5 (de)	1986-05-30
DE3343253A1 (de)	1985-02-21
JPS6042323A (ja)	1985-03-06
DE3343253C2 (fr)	1989-07-20
JPH0130807B2 (fr)	1989-06-22

Similar Documents

Publication	Publication Date	Title
DE69730834T2 (de)	2005-10-06	Verfahren zur herstellung von festen oralen dosierungsformen von valsartan
DE3030622C2 (de)	1996-05-30	Teilbare Tablette mit Retardeffekt für die Abgabe von Metoprolol oder Oxprenolol
DE4140689B4 (de)	2007-11-22	Inhalationspulver und Verfahren zu ihrer Herstellung
FI111605B (fi)	2003-08-29	Menetelmä veteen dispergoituvien tablettien valmistamiseksi
AU697982B2 (en)	1998-10-22	Paroxetine tablets and process to prepare them
EP1439829B1 (fr)	2005-09-07	Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif
DE3132614A1 (de)	1982-05-19	Suspension mikroverkapselten bacampicillin-saeureadditionssalzes fuer orale, insbesondere paediatrische verabreichung
DE10038108A1 (de)	2001-08-02	Pharmazeutische Zusammensetzungen
EP2045248A1 (fr)	2009-04-08	Procédé de prévention de la coloration de catéchines et composition de dentifrice
CA1219219A (fr)	1987-03-17	Comprimes de fluorure de sodium a liberation progressive, methode de production desdits comprimes et methode de traitement de l'osteoporose
EP1392314B1 (fr)	2006-12-20	NOUVELLE UTILISATION DU 2-[2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on
EP2714013B1 (fr)	2019-02-20	Mélange pulvérulent pour la préparation de comprimés contenant du lévétiracétam
EP2515852B1 (fr)	2016-03-02	Comprimé orodispersible contenant une base de sildenafil compactée
JP2001501643A (ja)	2001-02-06	神経障害性疼痛の処置に有用な鎮痙性誘導体
DE60013526T2 (de)	2005-11-17	Zusammensetzung enthaltend Verbindungen mit adrenergischer Aktivität und pflanzliche Extrakten von Crataegus und Gingko zur Behandlung von Übergewicht und Fettleibigkeit
Ekaluo et al.	2008	Effect of chloroquine treatments on sperm count and weight of testes in male rats
DE602004005734T2 (de)	2007-12-27	Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung
DE69813083T2 (de)	2004-05-27	Kombination in feste Dosiermenge von Angiotensin-Converting-Enzyme-Hemmern mit Calcium-Kanal Antagonisten zur Behandlung von Herz-Kreislauferkrankungen
EP1121109B1 (fr)	2006-05-31	Formulation a liberation biphasique contenant du tramadol
WO2006053089A3 (fr)	2006-08-24	Methodes et formulations permettant de preparer des compositions pharmaceutiques contenant du bupropion
DE102013110608A1 (de)	2015-03-26	Substanz zur Hemmung von Gewebskalzifizierung, Gewebsfibrosierung und altersassoziierten Erkrankungen
US20070178118A1 (en)	2007-08-02	Physiologically active composition and preparing method thereof
DE60111254T2 (de)	2006-05-04	Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation
EP2259779B1 (fr)	2015-09-16	Comprimés améliorés contenant de l'isomalt et leurs procédés de fabrication
DE10164343A1 (de)	2002-08-29	Tablettierfähige Zusammensetzung mit Natrium Fosinopril

Legal Events

Date	Code	Title	Description
2004-03-17	MKEX	Expiry